AIM ImmunoTech Valuation

AIM Stock  USD 1.23  0.17  16.04%   
Today, the firm appears to be undervalued. AIM ImmunoTech shows a prevailing Real Value of $4.38 per share. The current price of the firm is $1.23. Our model approximates the value of AIM ImmunoTech from examining the firm fundamentals such as Return On Equity of -31.39, current valuation of 3.39 M, and Operating Margin of (94.12) % as well as evaluating its technical indicators and probability of bankruptcy. Key fundamental drivers impacting AIM ImmunoTech's valuation include:
Price Book
2.7248
Enterprise Value
3.4 M
Enterprise Value Ebitda
0.4928
Price Sales
35.9822
Enterprise Value Revenue
30.2288
Undervalued
Today
1.23
Please note that AIM ImmunoTech's price fluctuation is risky at this time. Calculation of the real value of AIM ImmunoTech is based on 3 months time horizon. Increasing AIM ImmunoTech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the AIM stock is determined by what a typical buyer is willing to pay for full or partial control of AIM ImmunoTech. Since AIM ImmunoTech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AIM Stock. However, AIM ImmunoTech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  1.23 Real  4.38 Target  13.99 Hype  1.25 Naive  1.1
The intrinsic value of AIM ImmunoTech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AIM ImmunoTech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
4.38
Real Value
10.04
Upside
Estimating the potential upside or downside of AIM ImmunoTech helps investors to forecast how AIM stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AIM ImmunoTech more accurately as focusing exclusively on AIM ImmunoTech's fundamentals will not take into account other important factors:
Earnings
Estimates
LowProjectedHigh
-1.94-1.94-1.94
Details
Hype
Prediction
LowEstimatedHigh
0.061.256.91
Details
Naive
Forecast
LowNext ValueHigh
0.021.106.76
Details
2 Analysts
Consensus
LowTarget PriceHigh
12.7313.9915.52
Details
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use AIM ImmunoTech's intrinsic value based on its ongoing forecasts of AIM ImmunoTech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against AIM ImmunoTech's closest peers.

AIM ImmunoTech Cash

1.86 Million

AIM ImmunoTech Total Value Analysis

AIM ImmunoTech is presently forecasted to have company total value of 3.39 M with market capitalization of 4.03 M, debt of 2.94 M, and cash on hands of 1.7 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the AIM ImmunoTech fundamentals before making security assessment based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
3.39 M
4.03 M
2.94 M
1.7 M

AIM ImmunoTech Investor Information

The company recorded a loss per share of 21.17. AIM ImmunoTech last dividend was issued on the 11th of June 2019. The entity had 1:100 split on the 12th of June 2025. AIM ImmunoTech may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.

AIM ImmunoTech Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AIM ImmunoTech has an asset utilization ratio of 1.97 percent. This suggests that the Company is making $0.0197 for each dollar of assets. An increasing asset utilization means that AIM ImmunoTech is more efficient with each dollar of assets it utilizes for everyday operations.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

AIM ImmunoTech Profitability Analysis

Considering the key profitability indicators obtained from AIM ImmunoTech's historical financial statements, AIM ImmunoTech's profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess AIM ImmunoTech's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
1995-01-31
Previous Quarter
-2.8 M
Current Value
-3.3 M
Quarterly Volatility
1.8 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
At this time, AIM ImmunoTech's Gross Profit is very stable compared to the past year. As of the 6th of February 2026, Gross Profit Margin is likely to grow to 0.99, while Pretax Profit Margin is likely to drop (123.02).
For AIM ImmunoTech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of AIM ImmunoTech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well AIM ImmunoTech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between AIM ImmunoTech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of AIM ImmunoTech over time as well as its relative position and ranking within its peers.

AIM ImmunoTech Earnings per Share Projection vs Actual

By analyzing AIM ImmunoTech's earnings estimates, investors can diagnose different trends across AIM ImmunoTech's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for AIM ImmunoTech is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
AIM ImmunoTech is projected to generate -1.935575 in earnings per share on the 31st of December 2025. AIM ImmunoTech earnings estimates show analyst consensus about projected AIM ImmunoTech EPS (Earning Per Share). It derives the highest and the lowest estimates based on AIM ImmunoTech's historical volatility. Many public companies, such as AIM ImmunoTech, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

AIM ImmunoTech Ownership Allocation

AIM ImmunoTech shows 3.85 percent of its outstanding shares held by insiders and 4.94 percent owned by other corporate entities.

AIM ImmunoTech Profitability Analysis

The company reported the last year's revenue of 170 K. Reported Net Loss for the year was (17.32 M) with profit before taxes, overhead, and interest of 17 K.

About AIM ImmunoTech Valuation

We use absolute and relative valuation methodologies to arrive at the intrinsic value of AIM ImmunoTech. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of AIM ImmunoTech based exclusively on its fundamental and basic technical indicators. By analyzing AIM ImmunoTech's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of AIM ImmunoTech's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of AIM ImmunoTech. We calculate exposure to AIM ImmunoTech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AIM ImmunoTech's related companies.
Last ReportedProjected for Next Year
Gross Profit125.1 K131.4 K
Pretax Profit Margin(117.16)(123.02)
Operating Profit Margin(133.75)(140.44)
Net Loss(117.16)(123.02)
Gross Profit Margin 0.94  0.99 

AIM ImmunoTech Current Valuation Indicators

AIM ImmunoTech's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final AIM ImmunoTech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as AIM ImmunoTech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use AIM ImmunoTech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes AIM ImmunoTech's worth.
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Biotechnology sector continue expanding? Could AIM diversify its offerings? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AIM ImmunoTech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(21.17)
Revenue Per Share
0.106
Quarterly Revenue Growth
(0.26)
Return On Assets
(0.95)
Return On Equity
(31.39)
AIM ImmunoTech's market price often diverges from its book value, the accounting figure shown on AIM's balance sheet. Smart investors calculate AIM ImmunoTech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since AIM ImmunoTech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that AIM ImmunoTech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AIM ImmunoTech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.